Literature DB >> 7559883

Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma.

S Vikić-Topić1, K P Raisch, L K Kvols, S Vuk-Pavlović.   

Abstract

The presence of transcripts for somatostatin receptor (SSTR) subtypes 1, 2, 3, and 4 was probed by reverse transcription and polymerase chain reaction in ribonucleic acid isolated from 46 malignant and 9 nonmalignant breast tissues, 15 carcinoid tumor tissues, and 13 renal cell carcinoma tissues. The transcripts for SSTR2 were amplified in all but 2 tissue samples, whereas transcripts for SSTR1, SSTR3, and SSTR4 were detected sporadically. In renal cell tumors, SSTR3 transcripts were completely absent. In breast cancer tissue, SSTR subtypes were transcribed independently of patient age, menstrual status, diagnosis, histological grade, and levels of estrogen receptor and progesterone receptor. The probability of finding transcripts for SSTR subtypes, P, was ranked differently for the three types of tumor tissues. For breast cancer, P2 > P3 = P1 > P4; for carcinoid tumors, P2 > P1 > P3 = P4; and for renal cell tumors, P2 > P1 > P4 > P3.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559883     DOI: 10.1210/jcem.80.10.7559883

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

2.  Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma.

Authors:  M Pilichowska; N Kimura; A Suzuki; R Yoshida; M Schindler; H Nagura
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma.

Authors:  Yuji Nakamoto; Takayoshi Ishimori; Yoichi Shimizu; Kohei Sano; Kaori Togashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-07       Impact factor: 9.236

4.  Post-operative surveillance in kidney cancer.

Authors:  Ofer Gofrit; Marina Orevi
Journal:  Ann Transl Med       Date:  2019-07

Review 5.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

6.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

7.  Differential expression of somatostatin receptors in medulloblastoma.

Authors:  J Guyotat; J Champier; G S Pierre; A Jouvet; P Bret; C Brisson; M F Belin; F Signorelli; M F Montange
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

Review 8.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

9.  Expression of somatostatin type 2A receptor correlates with estrogen receptor in human breast carcinoma.

Authors:  M Pilichowska; N Kimura; M Schindler; A Suzuki; R Yoshida; H Nagura
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

10.  Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide.

Authors:  B Van Den Bossche; E D'haeninck; F De Vos; R A Dierckx; S Van Belle; M Bracke; C Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.